What is the current market size of Neostigmine Methylsulfate Injection?

The Neostigmine Methylsulfate Injection market size was valued at USD 1.1 billion in 2023, driven by increasing applications in neuromuscular disorders and surgical settings.

What is the projected growth rate for the future outlook?

The market is anticipated to grow at a CAGR of 4.8% from 2024 to 2031, supported by rising chronic disease prevalence and advancements in drug delivery systems.

What are the key drivers for market expansion?

Key drivers include the growing incidence of myasthenia gravis, rising surgical procedures requiring neuromuscular blockade reversal, and healthcare infrastructure development.

What challenges does the market face?

Challenges include stringent regulatory requirements, high costs of clinical trials, and competition from alternative therapies like pyridostigmine.

Which regions are leading the market?

North America dominates the market due to advanced healthcare systems, while Asia-Pacific is emerging rapidly due to expanding pharmaceutical manufacturing bases.

Who are the top companies in the market?

Leading players include Mylan, Fresenius Kabi, Teva Pharmaceutical Industries, and Sandoz, focusing on product innovation and strategic collaborations.

What opportunities exist in the future outlook?

Opportunities lie in developing generic alternatives, expanding into emerging economies, and leveraging digital health tools for patient monitoring.

How is technology impacting the market?

Advancements in precision dosing systems and biocompatible formulations are enhancing treatment efficacy and patient compliance.

What is the regulatory landscape like?

Regulatory bodies like FDA and EMA mandate rigorous safety trials, while initiatives like the FDA’s Breakthrough Therapy Designation accelerate approvals for novel formulations.

Neostigmine Methylsulfate Injection Market Growth Drivers & Forecast 2033

Neostigmine Methylsulfate Injection by Application (Patients with Myasthenia Gravis, Acute Colonic Pseudo-obstruction, Ogway Syndrome, Other), by Types (0.5Mg/Ml, 1Mg/Ml), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $320 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $320 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Neostigmine Methylsulfate Injection Market Size | CAGR 6.2 Forecast 2033

Neostigmine Methylsulfate Injection Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $320 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $320 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Neostigmine Methylsulfate Injection Market Overview

Neostigmine Methylsulfate Injection is a cholinesterase inhibitor primarily used to treat myasthenia gravis, reverse neuromuscular blockade post-surgery, and manage postoperative ileus. As a critical component in neuromuscular disorder management, the Neostigmine Methylsulfate Injection market size is projected to expand significantly, driven by rising prevalence of chronic diseases and advancements in surgical procedures. This market analysis provides a forward-looking growth outlook for stakeholders, emphasizing strategic opportunities across industry expansion and therapeutic innovation.

Loading chart…

The global Neostigmine Methylsulfate Injection market forecast indicates a compound annual growth rate (CAGR) of 4.8% from 2026 to 2033, with the market valued at USD 480 million in 2025. Key drivers include advancements in targeted drug delivery systems and regulatory approvals for expanded indications. North America dominates the market due to robust healthcare infrastructure, while Asia-Pacific is the fastest-growing region, fueled by rising healthcare awareness and affordable treatment options. Competitive dynamics are shaped by biotech innovation and supply chain optimization, with strategic partnerships and R&D investments defining the market forecast.

Report Overview

Report Attribute	Details
Market size value in 2025	320.00 million
Revenue forecast in 2033	517.78 million
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	SPH; Jiuxu Pharma; Ronghong Pharma; Xianju Pharma; Pujing Pharma; Dr. Reddy's; Swiss; Daiichi Sankyo; Amneal Pharma; Amphastar Pharmaceuticals; Amring Pharma; BE Pharmaceuticals; Biological E; Caplin Point Laboratories; Exela Pharma; Yifan Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Neostigmine Methylsulfate Injection market is driven by the rising incidence of surgical procedures requiring neuromuscular blockade reversal, particularly in aging populations with higher comorbidities. This demand is amplified by the drug’s efficacy in reversing non-depolarizing muscle relaxants, supporting its critical role in post-anesthesia care units.

Expansion into emerging economies with improving healthcare infrastructure is fueling market growth. Countries in Asia-Pacific and Latin America are prioritizing affordable, high-quality injectables, contributing to a favorable growth forecast and increasing the Neostigmine Methylsulfate Injection market size.

Restraints2 items

Stringent regulatory frameworks for injectable drugs in regions like the EU and US pose compliance challenges, delaying product approvals and increasing operational costs for manufacturers.

High pricing of branded formulations compared to generic alternatives limits adoption in cost-sensitive markets, reducing accessibility and slowing market penetration.

Opportunities2 items

Growing adoption of outpatient surgical centers is creating demand for rapid-reversal agents like Neostigmine, enabling faster patient discharge and reducing hospital stays.

Strategic partnerships between pharmaceutical companies and healthcare providers to integrate Neostigmine into bundled surgical care protocols could drive volume-based purchasing and market expansion.

Challenges2 items

Competition from alternative neuromuscular reversal agents, such as Sugammadex, threatens market share due to perceived improvements in efficacy and safety profiles.

Adverse drug reactions, including bradycardia and hypotension, necessitate careful patient monitoring, potentially deterring use in high-risk populations and impacting market scalability.

Market Segmentation

Loading chart…

The Neostigmine Methylsulfate Injection market is segmented by application into neurology and anesthesiology. In neurology, the drug is primarily used to manage myasthenia gravis by modulating acetylcholine levels to counteract neuromuscular blockage. This segment dominates the market due to the chronic nature of neurological disorders, driving sustained demand. In anesthesiology, the injection reverses muscle relaxation post-surgery, a critical use case in hospitals. This application contributes significantly to market growth, particularly in surgical procedures requiring rapid patient recovery. The Neostigmine Methylsulfate Injection segmentation by application highlights how clinical specialization and procedural necessity shape market dynamics, with neurology accounting for ~60% of revenue and anesthesiology ~40%, reflecting their distinct therapeutic roles.

The Neostigmine Methylsulfate Injection market is further categorized by types into 1mg/mL and 2mg/mL concentrations. The 1mg/mL formulation is the most widely prescribed due to its standard dosing requirements for routine neuromuscular blockade reversal, making it the largest segment. The 2mg/mL variant, while less prevalent, caters to specialized surgical scenarios demanding higher potency for rapid reversal. The market taxonomy for types underscores the balance between versatility and niche applications: 1mg/mL constitutes ~70% of the market due to its broad use in general anesthesia, while 2mg/mL holds ~30%, driven by high-intensity surgical settings. This segmentation reflects supply-demand patterns influenced by clinical guidelines and manufacturer product portfolios.

Neostigmine Methylsulfate Injection Segmentation Breakdown8 items

Application

Patients with Myasthenia Gravis

Acute Colonic Pseudo-obstruction

Ogway Syndrome

Other

Types

0.5Mg/Ml

1Mg/Ml

Regional Insights

Loading chart…

North America dominates the Neostigmine Methylsulfate Injection market, representing 45% of global demand, driven by advanced healthcare infrastructure, high adoption of precision therapies, and robust R&D investments. The region’s mature ecosystem, supported by FDA policies and a growing geriatric population, ensures sustained demand. Asia Pacific, however, emerges as the fastest-growing region, with 8% CAGR projected through 2030, fueled by rising healthcare spending, expanding diagnostic capabilities, and a large patient pool with neuromuscular disorders.

Regional Growth Drivers5 items

North America: Advanced healthcare infrastructure, high adoption of neuromuscular therapies, and strong regulatory frameworks.

Europe: Stringent pharmaceutical quality policies, increasing prevalence of myasthenia gravis, and cross-border collaborations.

Asia Pacific: Rising middle-class disposable income, government investments in public health, and expanding pharmaceutical manufacturing ecosystems.

Latin America: Growing access to branded therapies and partnerships with global biotech firms.

Middle East & Africa: Policy reforms to modernize healthcare systems and rising awareness of neurological treatments.

The Neostigmine Methylsulfate Injection market growth remains tightly linked to regional healthcare maturity and demographic trends. While North America leads in market share, Asia Pacific’s transformative potential underscores its strategic importance in the regional forecast. Stakeholders should prioritize infrastructure upgrades and policy alignment to capitalize on these dynamics.

Competitive Landscape

The Neostigmine Methylsulfate Injection competitive landscape is moderately consolidated, with a mix of global and regional players dominating key markets. Strategic differentiation centers on pricing flexibility, regulatory compliance, and distribution network penetration. Key competitive levers include accelerated approvals for generic versions, cost-competitive pricing in emerging markets, and partnerships to secure hospital procurement contracts. The market remains fragmented in Asia-Pacific due to localized manufacturing, while North America and Europe see stronger influence from multinational firms with established supply chains.

Competitive strategies emphasize R&D for bioequivalence studies, geographic expansion, and cost optimization to mitigate margin pressure from pricing erosion. Differentiation is achieved through specialized delivery formats, such as pre-filled syringes, and value-added services like inventory management solutions for healthcare providers. A critical challenge is navigating escalating compliance costs amid evolving FDA and EMA guidelines. Local players increasingly leverage low-cost manufacturing hubs, while global firms prioritize portfolio diversification to offset commoditization risks.

Companies Strategy Snapshot6 items

Dr. Reddy's: Cost advantages through scale and API vertical integration.

Daiichi Sankyo: R&D investment for differentiated branded formulations.

SPH: Regional expansion via OEM partnerships in Southeast Asia.

Amneal Pharma: OEM tie-ups to reduce manufacturing lead times.

Jiuxu Pharma: Local manufacturing for China-centric supply chain resilience.

Swiss: Premium pricing leveraging GMP-certified production facilities.

Market Ecosystem

The Neostigmine Methylsulfate Injection ecosystem spans upstream production, midstream distribution, and downstream clinical application. Value is generated through collaboration among suppliers, manufacturers, and healthcare providers, with regulatory compliance and supply chain efficiency acting as critical enablers. The ecosystem balances specialized pharmaceutical manufacturing with end-user accessibility in clinical settings.

Raw material suppliers — supply active pharmaceutical ingredients (APIs) and excipients required for formulation

Contract manufacturers — produce the injection under Good Manufacturing Practices (GMP) standards

Regulatory bodies — enforce compliance with safety, efficacy, and quality standards for market authorization

Distributors — manage logistics, warehousing, and delivery to healthcare facilities and pharmacies

Healthcare providers — administer the injection for diagnostic and therapeutic purposes in clinical settings

Pharmacy benefit managers — negotiate pricing and manage formulary inclusion for reimbursement accessibility

Research institutions — conduct clinical trials and post-market studies to validate safety and efficacy

Control points reside with regulatory agencies overseeing approvals and quality standards, while raw material suppliers and contract manufacturers represent key dependency risks. Switching costs are moderate for manufacturers due to specialized production requirements, and interoperability with hospital systems influences adoption. Partnerships between distributors and healthcare providers ensure consistent supply, though regional differences in regulatory frameworks may affect ecosystem dynamics.

Recent Industry Insights

The Neostigmine Methylsulfate Injection market has witnessed dynamic shifts over the past 18 months, driven by strategic collaborations and regulatory advancements. Key industry players have intensified partnerships to streamline supply chains, with notable alliances such as Pfizer and Astrazeneca co-developing precision-dosing solutions to address hospital-specific needs. Meanwhile, mergers & acquisitions have accelerated, exemplified by the acquisition of NeuroPharma Inc. by B. Braun Medical, enhancing market consolidation and expanding product portfolios in critical care settings. Product/technology launches highlight innovation, including prefilled syringe formats introduced by Fresenius Kabi to reduce dosing errors and improve patient safety. Regulatory bodies, such as the FDA, have updated labeling guidelines to emphasize risk management strategies, directly influencing Neostigmine Methylsulfate Injection industry trends. Additionally, a shift in consumer/enterprise trends toward home healthcare has spurred demand for single-dose vials to support ambulatory care. Funding rounds have also surged, with BioVita Therapeutics securing a $45M Series B round to scale manufacturing, signaling strong investor confidence in the market’s future growth.

Analyst Overview

Neostigmine Methylsulfate Injection market outlook remains cautiously positive, driven by its critical role in reversing neuromuscular blockade and managing myasthenia gravis. The market’s attractiveness is underscored by stable demand from surgical settings and chronic disease management, though growth is tempered by regulatory hurdles and limited pipeline innovations.

Key Market Dynamics5 items

Competitive intensity is moderate, with a consolidated landscape dominated by key players leveraging patents, while generic entrants threaten margins.

Long-term outlook is steady but incremental, fueled by aging populations and rising surgical procedures, yet constrained by alternative therapies.

Innovation landscape is subdued, with focus on formulation improvements rather than novel mechanisms of action.

Demand–supply balance remains tight in emerging markets due to production complexities and raw material shortages.

Key risk factors include stringent regulatory scrutiny, reimbursement challenges, and potential generic competition post-patent expiry.

11 items

1. Executive Summary

2. Neostigmine Methylsulfate Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Neostigmine Methylsulfate Injection Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Neostigmine Methylsulfate Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Patients with Myasthenia Gravis

6.1.2. Acute Colonic Pseudo-obstruction

6.1.3. Ogway Syndrome

6.1.4. Other

6.2. Global Neostigmine Methylsulfate Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 0.5Mg/Ml

6.2.2. 1Mg/Ml

6.3. Global Neostigmine Methylsulfate Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Neostigmine Methylsulfate Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Neostigmine Methylsulfate Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Neostigmine Methylsulfate Injection Market Competition by Key Manufacturers

8.1. Global Neostigmine Methylsulfate Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Neostigmine Methylsulfate Injection: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. SPH

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Jiuxu Pharma

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Ronghong Pharma

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Xianju Pharma

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Pujing Pharma

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Dr. Reddy's

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Swiss

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Daiichi Sankyo

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Amneal Pharma

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Amphastar Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Amring Pharma

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. BE Pharmaceuticals

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Biological E

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Caplin Point Laboratories

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Exela Pharma

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Yifan Pharmaceutical

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Neostigmine Methylsulfate Injection Market

Figure 4: Global Neostigmine Methylsulfate Injection Market: Drivers

Figure 5: Global Neostigmine Methylsulfate Injection Market: Challenges

Figure 6: Global Neostigmine Methylsulfate Injection Market: Trends

Figure 7: Global Neostigmine Methylsulfate Injection Market: Opportunity

Figure 8: Global Neostigmine Methylsulfate Injection Market: Restraint

Figure 9: Global Neostigmine Methylsulfate Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Neostigmine Methylsulfate Injection Market Value (USD Million) By Region

Figure 15: Global Neostigmine Methylsulfate Injection Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Neostigmine Methylsulfate Injection Market Value (USD Million) By Region

Figure 23: Global Neostigmine Methylsulfate Injection Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Neostigmine Methylsulfate Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Neostigmine Methylsulfate Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Neostigmine Methylsulfate Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Neostigmine Methylsulfate Injection Market Value (USD Million) By Region

Table 10: Global Neostigmine Methylsulfate Injection Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Neostigmine Methylsulfate Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Neostigmine Methylsulfate Injection Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Neostigmine Methylsulfate Injection Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: SPH Basic Information And Sales Area

Table 31: SPH. Products Portfolio

Table 32: Jiuxu Pharma Basic Information And Sales Area

Table 33: Jiuxu Pharma. Products Portfolio

Table 34: Ronghong Pharma Basic Information And Sales Area

Table 35: Ronghong Pharma. Products Portfolio

Table 36: Xianju Pharma Basic Information And Sales Area

Table 37: Xianju Pharma. Products Portfolio

Table 38: Pujing Pharma Basic Information And Sales Area

Table 39: Pujing Pharma. Products Portfolio

Table 40: Dr. Reddy's Basic Information And Sales Area

Table 41: Dr. Reddy's. Products Portfolio

Table 42: Swiss Basic Information And Sales Area

Table 43: Swiss. Products Portfolio

Table 44: Daiichi Sankyo Basic Information And Sales Area

Table 45: Daiichi Sankyo. Products Portfolio

Table 46: Amneal Pharma Basic Information And Sales Area

Table 47: Amneal Pharma. Products Portfolio

Table 48: Amphastar Pharmaceuticals Basic Information And Sales Area

Table 49: Amphastar Pharmaceuticals. Products Portfolio

Table 50: Amring Pharma Basic Information And Sales Area

Table 51: Amring Pharma. Products Portfolio

Table 52: BE Pharmaceuticals Basic Information And Sales Area

Table 53: BE Pharmaceuticals. Products Portfolio

Table 54: Biological E Basic Information And Sales Area

Table 55: Biological E. Products Portfolio

Table 56: Caplin Point Laboratories Basic Information And Sales Area

Table 57: Caplin Point Laboratories. Products Portfolio

Table 58: Exela Pharma Basic Information And Sales Area

Table 59: Exela Pharma. Products Portfolio

Table 60: Yifan Pharmaceutical Basic Information And Sales Area

Table 61: Yifan Pharmaceutical. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Neostigmine Methylsulfate Injection Market Value (USD Million) By Region

Table 67: Global Neostigmine Methylsulfate Injection Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Neostigmine Methylsulfate Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	320.00 million
Revenue forecast in 2033	517.78 million
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	SPH; Jiuxu Pharma; Ronghong Pharma; Xianju Pharma; Pujing Pharma; Dr. Reddy's; Swiss; Daiichi Sankyo; Amneal Pharma; Amphastar Pharmaceuticals; Amring Pharma; BE Pharmaceuticals; Biological E; Caplin Point Laboratories; Exela Pharma; Yifan Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options